Blood Cancers Today
@blood_cancers
Translating Hematologic Oncology Discoveries into Practice.
ID: 1443228030093209607
http://www.bloodcancerstoday.com/ 29-09-2021 14:56:00
3,3K Tweet
1,1K Followers
265 Following
β In the AUGMENT-101 trial led by Ibrahim Aldoss, MD, of City of Hope, revumenib monotherapy achieved high ORR and MRD negativity rates in patients with KMT2Ar acute leukemias. π° Read more: buff.ly/4cPoggK
Had a great time at Society of Hematologic Oncology (SOHO) #SOHO2024 presenting about challenging MPN scenarios! I also learned a ton about anemia-directed therapies in MF from Stephen Oh and JAK2m clonal hematopoiesis from Lachelle Dawn!
πΈ #BehindTheScenes at #SOHO2024: John F. DiPersio Lab, of WashU Medicine/WUSM Department of Medicine, stops by for an interview! π Stay tuned for interviews and more conference coverage here: buff.ly/4cTomDS
π Presented at #SOHO2024: Luspatercept use in #MDS is associated with fewer patient visits and less resource use compared with ESAs. π Read more about the abstract led by Brian Ball of City of Hope. β‘οΈ buff.ly/47cRFQQ
β Coming up at #SOHO2024: The MPN session, chaired by Laura C. Michaelis of Medical College of Wisconsin, and John Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, begins at 10:10 a.m. CT with a talk titled "Optimizing Selection of Available JAK Inhibitors in MF" by Prithviraj Bose of MD Anderson Cancer Center.
Dr John Seymour giving Dr Michael Keating plenary award lecture at #SOHO24 Society of Hematologic Oncology (SOHO) First patient ever treated with venetoclax (previously called ABT-199) was in June 2011 in Australia with Dr Seymour. Amazing how this drug has changed the practice of leukemia care,
π John Seymour, MBBS, FRACP, PhD, of Peter Mac Cancer Centre, received the Michael J. Keating Outstanding Achievement Award at #SOHO2024!
π A study presented at #SOHO2024 investigated the therapeutic benefit associated with immune checkpoint inhibitors for the treatment of #MDS. π° Read more about the study by vanthana bharathi of Saint Peter's HCS. β‘οΈ buff.ly/3z9Q2Xw